Market research
HRTX Heron Therapeuti
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 60M
- P/E ratio
- Not available
- Analyst target
- 7
- Dividend yield
- Not available
- Beta
- 1.67
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US4277461020
- Market cap
- 60M
- P/E ratio
- Not available
- Analyst target
- 7
- Dividend yield
- Not available
- Beta
- 1.67
About
About Heron Therapeuti
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. Heron Therapeutics, Inc. was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. The company was founded in 1983 and is headquartered in Cary, North Carolina.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the HRTX discussion.
5 years, 4 months ago
Heron Therapeutics, Inc is currently in a long term downtrend where the price is trading 16.6% below its 200 day moving average.
From a valuation standpoint, the stock is 98.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 17.0.
Heron Therapeutics, Inc's total revenue sank by 41.3% to $21M since the same quarter in the previous year.
Its net income has dropped by 7.5% to $-62M since the same quarter in the previous year.
Finally, its free cash flow fell by 78.3% to $-55M since the same quarter in the previous year.
Based on the above factors, Heron Therapeutics, Inc gets an overall score of 1/5.